Your browser doesn't support javascript.
Comparative Genomics and Characterization of SARS-CoV-2 P.1 (Gamma) Variant of Concern From Amazonas, Brazil.
Zimerman, Ricardo Ariel; Ferrareze, Patrícia Aline Gröhs; Cadegiani, Flavio Adsuara; Wambier, Carlos Gustavo; Fonseca, Daniel do Nascimento; de Souza, Andrea Roberto; Goren, Andy; Rotta, Liane Nanci; Ren, Zhihua; Thompson, Claudia Elizabeth.
  • Zimerman RA; Hospital da Brigada Militar, Porto Alegre, Brazil.
  • Ferrareze PAG; Graduate Program in Health Sciences, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, Brazil.
  • Cadegiani FA; Corpometria Institute, Brasília, Brazil.
  • Wambier CG; Department of Dermatology, Warren Alpert Medical School of Brown University, Providence, RI, United States.
  • Fonseca DDN; Samel and Oscar Nicolau Hospitals, Manaus, Brazil.
  • de Souza AR; Samel and Oscar Nicolau Hospitals, Manaus, Brazil.
  • Goren A; Applied Biology, Inc., Irvine, CA, United States.
  • Rotta LN; Graduate Program in Health Sciences, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, Brazil.
  • Ren Z; Suzhou Kintor Pharmaceutical, Inc., Suzhou, China.
  • Thompson CE; Graduate Program in Health Sciences, Universidade Federal de Ciências da Saúde de Porto Alegre, Porto Alegre, Brazil.
Front Med (Lausanne) ; 9: 806611, 2022.
Artículo en Inglés | MEDLINE | ID: covidwho-1731797
ABSTRACT

BACKGROUND:

P.1 lineage (Gamma) was first described in the State of Amazonas, northern Brazil, in the end of 2020, and has emerged as a very important variant of concern (VOC) of SARS-CoV-2 worldwide. P.1 has been linked to increased infectivity, higher mortality, and immune evasion, leading to reinfections and potentially reduced efficacy of vaccines and neutralizing antibodies.

METHODS:

The samples of 276 patients from the State of Amazonas were sent to a central referral laboratory for sequencing by gold standard techniques, through Illumina MiSeq platform. Both global and regional phylogenetic analyses of the successfully sequenced genomes were conducted through maximum likelihood method. Multiple alignments were obtained including previously obtained unique human SARS-CoV-2 sequences. The evolutionary histories of spike and non-structural proteins from ORF1a of northern genomes were described and their molecular evolution was analyzed for detection of positive (FUBAR, FEL, and MEME) and negative (FEL and SLAC) selective pressures. To further evaluate the possible pathways of evolution leading to the emergence of P.1, we performed specific analysis for copy-choice recombination events. A global phylogenomic analysis with subsampled P.1 and B.1.1.28 genomes was applied to evaluate the relationship among samples.

RESULTS:

Forty-four samples from the State of Amazonas were successfully sequenced and confirmed as P.1 (Gamma) lineage. In addition to previously described P.1 characteristic mutations, we find evidence of continuous diversification of SARS-CoV-2, as rare and previously unseen P.1 mutations were detected in spike and non-structural protein from ORF1a. No evidence of recombination was found. Several sites were demonstrated to be under positive and negative selection, with various mutations identified mostly in P.1 lineage. According to the Pango assignment, phylogenomic analyses indicate all samples as belonging to the P.1 lineage.

CONCLUSION:

P.1 has shown continuous evolution after its emergence. The lack of clear evidence for recombination and the positive selection demonstrated for several sites suggest that this lineage emergence resulted mainly from strong evolutionary forces and progressive accumulation of a favorable signature set of mutations.
Palabras clave

Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Tipo de estudio: Estudio experimental Tópicos: Vacunas / Variantes País/Región como asunto: America del Sur / Brasil Idioma: Inglés Revista: Front Med (Lausanne) Año: 2022 Tipo del documento: Artículo País de afiliación: Fmed.2022.806611

Similares

MEDLINE

...
LILACS

LIS


Texto completo: Disponible Colección: Bases de datos internacionales Base de datos: MEDLINE Tipo de estudio: Estudio experimental Tópicos: Vacunas / Variantes País/Región como asunto: America del Sur / Brasil Idioma: Inglés Revista: Front Med (Lausanne) Año: 2022 Tipo del documento: Artículo País de afiliación: Fmed.2022.806611